X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Cipla: Time for a relook? - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Jun 7, 2000

    Cipla: Time for a relook?

    One of India’s premier pharmaceutical companies, Cipla’s stock price has come off 45% from its level of Rs 1,331 over the last six months. The concerns primarily relate to the continuing overall slowdown in the pharmaceutical sector, which would affect Cipla’s growth too and the fact that the exports of AIDS drug to South Africa may not be such a hot opportunity in the absence of compulsory licensing.

    Over 35% of the company’s Rs 7,593 m turnover in FY 2000 accrued from antibiotics which have been the worst hit since the last year’s slowdown. Cipla’s products in this segment include Novamox (bulk drug: amoxycillin), Novaclox (cloxacillin combination), Ciplin (trimothoprim +sulphamethaxole combination), Ciplox (ciplofloxacin) and Norfloxacin (norfloxacin). The company responded by aggressively venturing into unbranded generics to maintain market share. Their share in the turnover reportedly increased in the last year from 5% of turnover in the previous year to 12% of the turnover.

    In the coming year’s quinolones such as ciprofloxacin, norfloxacin (these account for around 20% of the company’s turnover) are expected to gain market share at the expense of the older antibiotics (ampicillin and amoxycillin) and macrolides (erythromycin, clarithomycin and azithromycin) which account for approximately another 15% of the company’s turnover.

    Last year Cipla became the first Indian company to manufacture and market an anti–AIDS pill, branded Nivimune. The company priced its tablet at Rs 135 per tablet as against Rs 344 for an imported tablet. The pill, it was claimed reduced the risk of transmission of the AIDS virus during childbirth by almost 50%. Apart from the lucrative domestic market, it was the exports to the South African market (where almost one out of four people is infected with the HIV virus) which could have led to an explosive growth for the company. However, with original patent holders such as Glaxo, Boehringer, Merck also announcing that they would supply the therapy at significantly discounted prices it seems unlikely the South African government would go for compulsory licensing (under this policy patented products can be licensed out to generic players in a country if the drug has ‘substantial public health benefit’). In the absence of compulsory licensing, the window of opportunity for Cipla to export the drug to South Africa, would automatically be closed.

    That’s as far as the negatives go. The positives include the company’s increasing success in the anti–asthama market. These are expected to account for almost 22% of the company’s turnover in the coming year. Last year the company launched non–CFC based inhalers under the brand name Asthalin HFA. With CFC based inhalers to be compulsorily phased out by 2010, this segment should see a good growth in the future. In India the asthama market is estimated to be in the range of Rs 2 bn and is growing at the range of 15% annually. While the beta agonist based inhalers (these are terbulatine salmetrol and salbutamol based) will grow at the market rates, the new class of asthma drugs (beclomethasone and budesonide) are showing faster growth of over 20% per annum. Cipla has a presence in all the molecules in the asthma segment.

    Another fast growing segment for the company is the cardiovascular segment. These account for 10% of the company’s turnover at present. The total market is around 3 bn and growing much faster at 25% per annum. Globally, cardiovascular diseases such as angina (a suffocating pain in the heart which occurs when the blood supply to the heart muscles is inadequate), hypertension (high blood pressure in the arteries) and high cholesterol account for a US $ 30 bn market and these are expected to continue to grow by 7% plus in the coming years. Cipla has products based on newer molecules such as Metolar (Metoprolol) and Zaart (Losartan) and although their contribution to the total turnover is still small these can be expected to grow at market rates of growth.

    The upside could come from the exports of the bulk drug omeprazole (anti–ulcer). The company has reportedly tied up with a generic company based in the USA for the exports of this drug and with Prisolec (Astra Zeneca’s $ 4.1 bn blockbuster) going of patent in October 2001, this could give Cipla a good opportunity over the next few years.

    At the current price of Rs 738, the stock discounts the expected EPS (Rs 25.3) of FY 2001 assuming a 15% growth in the bottomline by 29.1 times. The market capitalisation to sales ratio works out to 4.8 times assuming a 20% topline growth in FY 2001. At these valuations though there may be no dramatic undervaluation, the recent underperformance (see chart) could provide investors with a long term opportunity to invest in one of India’s premier pharma companies.

     

     

    Equitymaster requests your view! Post a comment on "Cipla: Time for a relook?". Click here!

      
     

    More Views on News

    Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

    Mar 8, 2017

    Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

    Sep 19, 2016

    Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    CIPLA SHARE PRICE


    Aug 18, 2017 (Close)

    TRACK CIPLA

    CIPLA - PANACEA BIOTECH COMPARISON

    Compare Company With Charts

    COMPARE CIPLA WITH

    MARKET STATS